Board of Directors

Duke Collier
Executive Chairman

Earl M. (Duke) Collier, Jr. is executive chairman of Arsenal Medical, chief executive officer of 480 Biomedical and a senior advisor to Polaris Venture Partners. For many years, Mr. Collier was executive vice president at Genzyme Corporation. He has also served as president of Vitas Healthcare, a partner at the Washington, DC-based law firm of Hogan and Hartson and as deputy administrator of the Health Care Finance Administration (now CMS) in the Department of Health and Human Services. Mr. Collier sits on the boards of Arsenal Medical, Pervasis Therapeutics, Newton-Wellesley Hospital and the Boston Athenaeum. He earned a Bachelor of Arts at Yale University and and received a law degree from the University of Virginia Law School.

George Whitesides, Ph.D.
Woodford L. and Ann A. Flowers University Professor, Harvard University
Co-Founder

Dr. Whitesides joined Harvard’s Department of Chemistry in 1982 and served as department chairman from 1986 to 1989. From 1963 to 1982, he was a faculty member at Massachusetts Institute of Technology. Dr. Whitesides held advisory positions on the National Research Council, National Science Foundation and the Department of Defense’s Defense Advanced Research Projects Agency (DARPA), and he is a member of the American Academy of Arts and Sciences, National Academy of Sciences, National Academy of Engineering and the American Philosophical Society, among other organizations. He has received dozens of honors, including the American Chemical Society (ACS) Award in Pure Chemistry (1975), the Arthur C. Cope Award (1995), the DARPA Award for Significant Technical Achievement (1996), the National Medal of Science (1998), the Von Hippel Award (2000), the Kyoto Prize (2003), the Dan David Award (2005), the Welch Award (2005), the Priestley Award (2007), the American Institute of Chemists Gold Medal (2007), the Prince of Asturias Foundation Award (2008), the Nanoscience Prize (2008), the Wheland Medal (2008) and the Benjamin Franklin Medal in Chemistry (2009). In addition to Aresenal Medical, George is a co-founder of a number of companies including Genzyme, GelTex, Theravance and 480 Biomedical. He received a Bachelor of Arts from Harvard University in 1960 and a doctorate from the California Institute of Technology in 1964.

Robert Langer, D.Sc.
David H. Koch Institute Professor, Massachusetts Institute of Technology
Co-Founder

Robert S. Langer is one of 14 Institute Professors (the highest honor awarded to a faculty member) at the Massachusetts Institute of Technology (MIT). Dr. Langer has written approximately 1,130 articles. He also has approximately 800 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed more than 250 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history. He served as a member of the U.S. FDA’s SCIENCE Board, the agency’s highest advisory board, from 1995-2002, and as its chairman from 1999-2002. Dr. Langer has received more than 200 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; and the 2008 Millennium Prize, the world’s largest technology prize. He is the only engineer to receive the Gairdner Foundation International Award; 76 recipients of this award have subsequently received a Nobel Prize. Among his multiple accolades, Forbes Magazine selected Dr. Langer as "one of the 15 innovators worldwide who will reinvent our future."

Carmichael Roberts, Ph.D.
General Partner, North Bridge Venture Partners
Co-Founder

Carmichael Roberts joined North Bridge Venture Partners in 2007 where he focuses mainly on early-stage companies that make products using unique chemistry and materials inventions. Prior to North Bridge, Dr. Roberts co-founded and served as the president and chief executive officer of Arsenal Medical. Dr. Roberts has co-founded other ventures, including several focused on life sciences. In 1999, Dr. Roberts was named one of the world’s top 100 young entrepreneurs by MIT’s Technology Review. Prior to his entrepreneurial career, Dr. Roberts worked in business development at GelTex Pharmaceuticals, which was acquired by Genzyme for $1.3 billion, and in new product and business development at Dow Chemical (formerly Union Carbide Corporation). Dr. Roberts received his Bachelor of Science and doctorate in organic chemistry from Duke University, and he completed his postdoctoral National Science Foundation fellowship at Harvard University. Dr. Roberts also holds a master’s degree in business administration from the MIT Sloan School of Management. He serves as an advisor for MIT’s Deshpande Center for Technological Innovation, Harvard’s Nanoscale Science and Engineering Center and the schools of Science and Engineering at Duke University.

Jamie Goldstein
Partner, North Bridge Venture Partners

Prior to joining North Bridge Venture Partners in 1998, Mr. Goldstein co-founded PureSpeech, a venture-backed speech recognition software and applications company targeting service providers and enterprise call centers. Mr. Goldstein served as vice president of sales and marketing, driving revenue through OEM relationships with leading PC manufacturers and voice services platform providers. PureSpeech was acquired by Voice Control Systems (NASDAQ: VCSI) and subsequently sold to Scansoft (NASDAQ: SSFT). Before PureSpeech Mr. Goldstein was an early employee with Symmetrix, a provider of manufacturing execution software that helped old-line manufacturing companies streamline their operations. Symmetrix grew to nearly 200 employees before its acquisition by SAIC. Mr. Goldstein’s diverse investment interests include software, storage, wireless, semiconductor and materials companies. He is a graduate of MIT in electrical engineering and the Harvard Graduate School of Business Administration. He is president of the board of the New England Venture Capital Association and a trustee of the MATCH School, a Boston-area charter school.

Terrance G. McGuire
Co-Founder and General Partner, Polaris Venture Partners

Terry McGuire is a co-founder and general partner of Polaris Venture Partners based in the Boston office. Mr. McGuire focuses on life sciences investments. Prior to starting Polaris, Mr. McGuire spent seven years at Burr, Egan, Deleage & Co. investing in early-stage medical and information technology companies. Mr. McGuire has co-founded three companies: Inspire Pharmaceuticals, AIR (Advanced Inhalation Research, Inc.) and MicroCHIPS. Mr. McGuire represents Polaris on the boards of directors of Acceleron Pharma, Adimab, Arsenal Medical, deCODE Genetics, Ironwood Pharmaceuticals, Life Line Screening, MicroCHIPS, Pulmatrix, SustainX Energy Storage Solutions and Trevena. He has also served on the boards of Akamai, Aspect Medical Systems, Cubist Pharmaceuticals, GlycoFi, Transform Pharmaceuticals and Remon Medical Technologies. Mr. McGuire is chairman emeritus of the National Venture Capital Association. He chairs the board of overseers of the Thayer School of Engineering at Dartmouth College, and serves on the boards of MIT’s David Koch Institute for Integrative Cancer Research and the Arthur Rock Center for Entrepreneurship at Harvard Business School. Mr. McGuire holds a master’s degree in business administration from Harvard Business School, a Master of Science in engineering from The Thayer School at Dartmouth College and a Bachelor of Science in physics and economics from Hobart College. Mr. McGuire is a recipient of the 2009 Massachusetts Society for Medical Research Award and the 2005 Albert Einstein Award for Outstanding Achievement in the Life Sciences.

Guido Neels
Managing Director, Essex Woodlands Health Ventures

Guido Neels served as chief operating officer of Guidant Corporation, a world leader in the development of cardiovascular medical products, from May 2004 until his retirement in November 2005. Mr. Neels was responsible for the global operations of Guidant's four operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery and Endovascular Solutions. From December 2002 to May 2004, he was group chairman, office of the president at Guidant, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. From January 2000 to December 2002, he was president of Guidant for Europe, Middle East, Africa and Canada. He previously served as vice president of global marketing for Vascular Intervention and as managing director for German and Central European operations. From 1982 to 1994, until Guidant was spun off as an independent public company from Eli Lilly and Co., Mr. Neels held various general management and sales and marketing positions at Lilly in the U.S. and Europe.

Jimmy Rosen
Intersouth Partners

Jimmy Rosen joined the life science team at Intersouth in 2005. Previously, he spent 15 years in clinical, research and financial positions in the health care and biotechnology sectors. Mr. Rosen worked on a Robert Wood Johnson Foundation sponsored program at the UNC Lineberger Comprehensive Cancer Center. He was also an equity research analyst at Brean Murray & Co. for three years, covering biopharmaceuticals, genomics, generics, drug delivery and medical device companies. He has worked in clinical research roles at Duke University Medical Center’s Comprehensive Cancer Center and completed projects for the National Cancer Institute. At the beginning of his career in health care, Mr. Rosen spent five years in emergency medical services as a mountain search rescue and ambulance medic. Jimmy holds a Bachelor of Arts from Duke University, a master's degree in business administration from UNC-Chapel Hill’s Kenan-Flagler Business School and a Master of Science in public health from the UNC School of Public Health. He was a Carolina Venture Fellow at Kenan-Flagler and recipient of the Frank Hawkins Kenan Award for Excellence. In 2010, Mr. Rosen was awarded the Eisenhower Fellowship to study biotechnology and medical device innovation in Asia. He currently serves on the Dean’s Advisory Council and the Public Health Foundation Board for the UNC Gillings School of Global Public Health.